| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Biochemical
Sulfo-TAG NHS ester does not target biological receptors. Its primary molecular target is primary amine groups (-NH₂) on proteins, particularly lysine residues, with which it forms stable amide bonds. The compound is a labeling reagent used to conjugate ruthenium-based chemiluminescent tags to antibodies, proteins, and other amine-containing biomolecules for detection in immunoassays and electrochemiluminescence (ECL) assays. |
|---|---|
| ln Vitro |
Use Guidelines (The following is our recommended protocol. This is provided as a guide and should be modified according to your specific needs.)
1. Preparation of Working Solution Prepare Sulfo-Tag NHS-Ester at a concentration of 3 nmol/μL. 2. Antibody Labeling 1) For lyophilized antibodies, reconstitute directly with PBS buffer at pH 7.9. For antibodies in solution, perform buffer exchange using a Zeba desalting column with a 7,000 Da molecular weight cut-off, replacing the buffer with PBS at pH 7.9. 2) Determine the antibody concentration using a BCA protein assay kit and a microplate reader. 3) For the labeling step, add the 3 nmol/μL Sulfo-Tag NHS-Ester to the antibody at a molar ratio of 12:1, and mix for 2 hours at room temperature in the dark. 4) Use a Zeba desalting column to exchange the antibody buffer to PBS containing 0.05% sodium azide at pH 7.4. 5) Measure the absorbance of the protein conjugate at 455 nm using a NanoDrop to determine the labeling ratio of the sulfo-tag to the antibody. In vitro, Sulfo-TAG NHS ester is widely used for efficient antibody labeling by specifically conjugating to primary amine groups on proteins. It is a water-soluble labeling reagent used for bioconjugation and immunoassays. The NHS ester reacts with primary amines to form stable amide bonds, making it ideal for antibody functionalization. The ruthenium label provides electrochemiluminescent signal for detection in ECL-based assays such as immunoassays and nucleic acid detection. |
| ln Vivo |
In vivo activity is not applicable as this compound is an in vitro labeling reagent and is not administered to living organisms. It is used for labeling antibodies and proteins for diagnostic and research applications. Its utility is in immunoassays and bioconjugation, not in therapeutic applications. The compound is not intended for in vivo administration.
|
| Enzyme Assay |
In vitro non-cellular labeling assays with Sulfo-TAG NHS ester typically involve: (1) prepare a solution of the protein or antibody to be labeled in PBS or borate buffer (pH 7.5-8.5); (2) dissolve Sulfo-TAG NHS ester in water or DMSO at a suitable concentration; (3) mix the labeling reagent with the protein solution at molar ratios of 1:5 to 1:20 (protein:label); (4) incubate at room temperature for 30-60 minutes or at 4°C for 2-4 hours; (5) remove unreacted label by dialysis, gel filtration, or ultrafiltration; (6) determine the labeling ratio by measuring absorbance at the ruthenium characteristic wavelength; and (7) assess the activity of the labeled protein by appropriate assays.
|
| Cell Assay |
In vitro cell-based assays using Sulfo-TAG-labeled antibodies typically involve: (1) prepare Sulfo-TAG-labeled detection antibodies; (2) culture cells in appropriate medium; (3) fix and permeabilize cells if necessary; (4) incubate cells with primary antibody followed by Sulfo-TAG-labeled secondary antibody; (5) add ECL substrate; (6) measure chemiluminescent signal using a plate reader; (7) quantify target protein expression levels; and (8) compare results to standard curves for absolute quantification.
|
| Animal Protocol |
In vivo animal experiments are not applicable as this compound is an in vitro labeling reagent. It is not administered to animals. No pharmacokinetic or toxicological studies in animals are conducted for this material for therapeutic purposes. It is used exclusively for in vitro research and diagnostic applications.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable as this compound is an in vitro labeling reagent, not a drug. It is not administered systemically. Its chemical properties include a molecular weight of 1185.12, high water solubility due to the sulfonate groups, and a ruthenium tris-bipyridine core that provides electrochemiluminescent properties. The NHS ester group is reactive with primary amines.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Sulfo-TAG NHS ester is relevant to occupational exposure as a chemical reagent. The compound contains ruthenium, which may be toxic at high concentrations. It is for research use only and is not intended for human consumption. Use appropriate personal protective equipment when handling, including gloves and safety goggles. Work in a well-ventilated area. Avoid inhalation and skin contact. Standard laboratory safety practices should be followed.
|
| References | |
| Additional Infomation |
168441741
This compound is also known as Sulfo-TAG NHS ester disodium. It is a highly water-soluble chemiluminescent labeling reagent used for bioconjugation and immunoassays. It is widely used for efficient antibody labeling by specifically conjugating to primary amine groups on proteins. The NHS ester reacts with lysine residues to form stable amide bonds. This product is not a drug and has no clinical trial or regulatory approval status. |
| Molecular Formula |
C43H39N7NA2O16RUS4
|
|---|---|
| Molecular Weight |
1185.12
|
| Exact Mass |
1185.01749
|
| CAS # |
482618-42-8
|
| PubChem CID |
168441741
|
| Appearance |
Solid powder ; Orange to red
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
73
|
| Complexity |
1880
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1C=[N+]2C(C3=CC(CCCC(ON4C(=O)CCC4=O)=O)=CC=[N+]3[Ru]342([N+]2=CC=C(CS(=O)(=O)[O-])C=C2C2=CC(CS(=O)([O-])=O)=CC=[N+]32)[N+]2=CC=C(C=C2C2[N+]4=CC=C(CS(=O)(=O)[O-])C=2)CS(=O)([O-])=O)=CC=1C.[Na+].[Na+]
|
| InChi Key |
GPSOIZKEYLTPJQ-UHFFFAOYSA-J
|
| InChi Code |
InChI=1S/C19H19N3O4.2C12H12N2O6S2.2Na.Ru/c1-13-7-9-20-15(11-13)16-12-14(8-10-21-16)3-2-4-19(25)26-22-17(23)5-6-18(22)24;2*15-21(16,17)7-9-1-3-13-11(5-9)12-6-10(2-4-14-12)8-22(18,19)20;;;/h7-12H,2-6H2,1H3;2*1-6H,7-8H2,(H,15,16,17)(H,18,19,20);;;/q;;;2*+1;+2/p-4
|
| Chemical Name |
disodium;(2,5-dioxopyrrolidin-1-yl) 4-[2-(4-methyl-2-pyridinyl)-4-pyridinyl]butanoate;ruthenium(2+);bis([2-[4-(sulfonatomethyl)-2-pyridinyl]-4-pyridinyl]methanesulfonate)
|
| Synonyms |
482618-42-8; Ruthenate(2-), bis((2,2'-bipyridine)-4,4'-dimethanesulfonato(2-)-kappaN1,kappaN1')(1-(4-(4'-methyl(2,2'-bipyridin)-4-yl-kappaN1,kappaN1')-1-oxobutoxy)-2,5-pyrrolidinedione)-, sodium (1:2), (OC-6-31)-; Ruthenate(2-), bis[[2,2'-bipyridine]-4,4'-dimethanesulfonato(2-)-kappaN1,kappaN1'][1-[4-(4'-methyl[2,2'-bipyridin]-4-yl-kappaN1,kappaN1')-1-oxobutoxy]-2,5-pyrrolidinedione]-, sodium (1:2), (OC-6-31)-; RefChem:883997; 853-382-3;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~84.38 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8438 mL | 4.2190 mL | 8.4380 mL | |
| 5 mM | 0.1688 mL | 0.8438 mL | 1.6876 mL | |
| 10 mM | 0.0844 mL | 0.4219 mL | 0.8438 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
